Advent Pharma Ltd. (DSE:ADVENT)

Advent Pharma Statistics

Total Valuation

Advent Pharma has a market cap or net worth of BDT 1.33 billion. The enterprise value is 1.40 billion.

Market Cap	1.33B
Enterprise Value	1.40B

Important Dates

The last earnings date was Sunday, October 26, 2025.

Earnings Date	Oct 26, 2025
Ex-Dividend Date	Nov 23, 2025

Share Statistics

Advent Pharma has 93.13 million shares outstanding.

Current Share Class	93.13M
Shares Outstanding	93.13M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 27.35.

PE Ratio	27.35
Forward PE	n/a
PS Ratio	2.78
PB Ratio	0.88
P/TBV Ratio	0.88
P/FCF Ratio	60.24
P/OCF Ratio	13.77
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.78, with an EV/FCF ratio of 63.45.

EV / Earnings	28.81
EV / Sales	2.93
EV / EBITDA	8.78
EV / EBIT	14.63
EV / FCF	63.45

Financial Position

The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.05.

Current Ratio	1.49
Quick Ratio	0.94
Debt / Equity	0.05
Debt / EBITDA	0.47
Debt / FCF	3.37
Interest Coverage	12.11

Financial Efficiency

Return on equity (ROE) is 3.26% and return on invested capital (ROIC) is 3.83%.

Return on Equity (ROE)	3.26%
Return on Assets (ROA)	3.15%
Return on Invested Capital (ROIC)	3.83%
Return on Capital Employed (ROCE)	5.57%
Revenue Per Employee	1.54M
Profits Per Employee	156,045
Employee Count	312
Asset Turnover	0.25
Inventory Turnover	4.14

Taxes

In the past 12 months, Advent Pharma has paid 9.54 million in taxes.

Income Tax	9.54M
Effective Tax Rate	16.39%

Stock Price Statistics

The stock price has decreased by -12.80% in the last 52 weeks. The beta is 0.36, so Advent Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.36
52-Week Price Change	-12.80%
50-Day Moving Average	15.32
200-Day Moving Average	15.19
Relative Strength Index (RSI)	39.03
Average Volume (20 Days)	155,159

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Advent Pharma had revenue of BDT 478.96 million and earned 48.69 million in profits. Earnings per share was 0.52.

Revenue	478.96M
Gross Profit	178.08M
Operating Income	95.91M
Pretax Income	58.23M
Net Income	48.69M
EBITDA	159.23M
EBIT	95.91M
Earnings Per Share (EPS)	0.52

Balance Sheet

The company has 3.61 million in cash and 74.52 million in debt, giving a net cash position of -70.91 million or -0.76 per share.

Cash & Cash Equivalents	3.61M
Total Debt	74.52M
Net Cash	-70.91M
Net Cash Per Share	-0.76
Equity (Book Value)	1.51B
Book Value Per Share	16.24
Working Capital	90.34M

Cash Flow

In the last 12 months, operating cash flow was 96.69 million and capital expenditures -74.59 million, giving a free cash flow of 22.11 million.

Operating Cash Flow	96.69M
Capital Expenditures	-74.59M
Free Cash Flow	22.11M
FCF Per Share	0.24

Margins

Gross margin is 37.18%, with operating and profit margins of 20.02% and 10.16%.

Gross Margin	37.18%
Operating Margin	20.02%
Pretax Margin	12.16%
Profit Margin	10.16%
EBITDA Margin	33.24%
EBIT Margin	20.02%
FCF Margin	4.62%

Dividends & Yields

This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.70%.

Dividend Per Share	0.10
Dividend Yield	0.70%
Dividend Growth (YoY)	-50.00%
Years of Dividend Growth	n/a
Payout Ratio	30.31%
Buyback Yield	n/a
Shareholder Yield	0.69%
Earnings Yield	3.66%
FCF Yield	1.66%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on February 28, 2022. It was a forward split with a ratio of 1.02.

Last Split Date	Feb 28, 2022
Split Type	Forward
Split Ratio	1.02

Scores

Advent Pharma has an Altman Z-Score of 3.89 and a Piotroski F-Score of 5.

Altman Z-Score	3.89
Piotroski F-Score	5